Match Document Document Title
DE102011118022B4 Antibodies against the prostate-specific stem cell antigen and its use  
The invention relates to recombinant antibodies that bind to prostate-specific stem cell antigen (PSCA). The antibody according to the invention contains complementarity-determining regions (CDR)...
DE60017711T3 ANALOGUE OF NUCLEOSIDES AND OLIGONUCLEOTIDES  
The object of the present invention is to provide novel oligonucleotide analogues, which exhibit antisense or antigene activity having excellent stability, or exhibit excellent activity as a...
DE102007063902B3 Aptamers that bind to a target molecule involved in hemostasis  
Aptamer that binds to a target molecule involved in hemostasis, the aptamer being an aptamer that binds to activated protein C, the aptamer having a dissociation constant KD binds to activated...
DE102011018627B4 Modified nucleotides  
Connection with structure (I): or a salt, a conjugate base, a tautomer or a dissociated form thereof, wherein P1 is a phosphate group; P2 is a phosphate group; Nus is a nucleoside structural unit...
DE112012003416B4 Process for the preparation of 2- (4-methoxycarbonylpyrazol-1-yl) adenosine and 2- (4-ethoxycarbonylpyrazol-1-yl) adenosine  
A process for the preparation of 2- (4-methoxycarbonylpyrazol-1-yl) adenosine of the formula Ia and 2- (4-ethoxycarbonylpyrazol-1-yl) adenosine of the formula Ib by reaction of...
DE69727260T3 A process for producing L-lysine  
A coryneform bacterium in which a DNA coding for a diaminopimelate decarboxylase and a DNA coding for a diaminopimelate dehydrogenase are enhanced is cultivated in a medium to allow L-lysine to be...
DE60310944T3 OTHER NEW FORMS OF INTERFERING RNA MOLECULES  
The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double- stranded structure comprises a first strand and a second strand, whereby the first...
DE102015009439B4 Triple target HIV-1 NAT for the detection of all known genotypes  
A primer / sample set for the detection of HIV, in particular HIV-1, comprising at least one primer / sample set 1 consisting of oligonucleotides comprising SEQ ID NOs 1, 2 and 3; Primer / sample...
DE102006012414B4 Chemical process for the production of degraded polygalactomannans  
A process for recovering degraded polygalactomannan comprising the steps of: providing a suspension of a polygalactomannan in an aqueous alcoholic solution having an alcohol concentration between...
DE202017002052U1 Nucleoside pearl necklaces sequencing  
An apparatus for DNA sequencing by passing a single-stranded DNA or RNA strand with anhybridized, chemically modified (nucleo-) bases, nucleosides or nucleotides by a biological or non-biological...
DE60038248T3 disaccharide  
The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to methods of preparation thereof. The novel mono- and disaccharide derivatives have...
DE102015219651A1 Compositions containing sugar amine and fatty acid  
Compositions are described containing a) one or more sugar amines of the formula (I) wherein R1 and R2 are independently H, CH3 or 2-hydroxyethyl and / or one or more corresponding protonated...
DE60028358T3 HMG1 ANTAGONISTS FOR THE TREATMENT OF IGNITION  
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount...
DE102007041476B4 Aptamers that bind to a target molecule involved in hemostasis  
Aptamer that binds to a target molecule involved in hemostasis, the aptamer being a thrombin-binding fusion aptamer, comprising at least two thrombin-binding aptamers and at least one linker, the...
DE202008018643U1 Nucleoside phosphoramidate drugs  
Compound according to the following formula: in which (a) R1 Is hydrogen, methyl, ethyl, n-propyl, i-propyl or a substituted or unsubstituted phenyl, the substituent of the substituted phenyl...
DE102015011780A1 New glutaminylcyclase inhibitors  
The invention relates to a compound of the formula (I) for use as a glutaminylcyclase inhibitor, to a composition containing the compound for use as a QC inhibitor and to processes for the...
DE102015214603A1 Phosphorus-containing aminoglycoside salts  
The object is to provide aminoglycoside compounds which ensure a sustained release of aminoglycoside over clinically relevant periods in therapeutically effective concentrations. Aminoglycoside...
DE112012003470B4 Process for the preparation of 2- [4 - [(methylamino) carbonyl] -1-H-pyrazol-1-yl] adenosine monohydrate  
Process for the preparation of 2- [4 - [(methylamino) carbonyl] -1-H-pyrazol-1-yl] adenosine monohydrate of the formula I. comprising the steps: a) Allowing 2- (4-methoxycarbonylpyrazol-1-yl)...
DE69935782T3 Breast cancer resistance protein (BCRP) and DNA encoding it  
The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs.
DE102015219343A1 A process for preparing galactose derived from marine algae using agarase  
A method for preparing galactose by means of an enzymatic treatment of a red algal residue is provided. The process for preparing galactose comprises: preparing a residue; Treating the residue...
DE102015008536A1 Discontinuous oligonucleotide ligands  
The present invention relates to an oligonucleotide conjugate K of the structure or a pharmaceutically active salt thereof, wherein RNA1, RNA2, RNA3 and RNA4 are each strands of a ribonucleic acid...
DE19549875B4 Use of magnetic particles to isolate nucleic acids  
Magnetic particles with an outer glass surface that is essentially pore-free or has pores with a diameter of less than 10 nm and ferromagnetic particles with a glass surface can preferably be used...
DE112015001085T5 Antibodies, uses and procedures  
The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
DE102015216558A1 PROCEDURE AND TEST KIT FOR FAST ISOLATION OF NUCLEIC ACIDS BY SMOKE SURFACES  
The invention relates to a method for isolating nucleic acids from nucleic acid-containing samples, characterized in that free nucleic acids released by lysis are bound to a solid phase with a...
DE102014018527A1 CYCLO - NUCLEOSIDE  
The present invention relates to cyclo-nucleosides of the formula (I) where R is hydrogen, alkyl or acyl, R1 is hydrogen or alkyl, X is hydrogen or the radical OR and Y is oxygen or NH.
DE69937439T3 Improved deprotection procedure for the synthesis of oligomer compounds  
Synthetic processes are provided wherein oligomeric compounds are prepared having phosphodiester, phosphorothioate, phosphorodithioate, or other covalent linkages. The oligomers have substantially...
DE10328887B4 Alkaline protease  
Alkaline protease with a prepro sequence, the prepro sequence being a mutated sequence of the amino acid sequence of SEQ ID NO. 1 represents or an amino acid sequence with at least 80%, 87%, 90%,...
DE102015008631A1 Medicines for cancer therapy  
The present invention relates to novel chemical compounds, in particular benzophenone derivatives, which are suitable as active ingredients in the medicinal treatment of cancer.
DE202014010612U1 Double Run cassette  
Cassette (1) for synthesizing a plurality of batches of a [18F] -labelled positron emission tomography (PET) -Tracers, said cartridge comprising: (i) an anion exchange column (3, 4) for each of...
DE69829760T3 BI AND TRI-CYCLIC - NUCLEOSIDE, NUCLEOTIDE AND Oligonucleotide Analogs  
The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs ( L ocked...
DE19858588B4 The dye-labeled oligonucleotide for labeling a nucleic acid molecule  
The dye-labeled oligonucleotide for labeling a a target sequence section comprising a nucleic acid molecule, wherein the dye-labeled oligonucleotide comprises the following components: a) - a loop...
DE102014013397A1 Perlenketten sequencing  
There will be described using labeled nucleotides, a method for sequencing nucleic acids. Firstly, the nucleotides on the ribose or deoxyribose may be labeled and be integrated by means of a...
DE102014112055A1 Di- and triphosphate drugs  
The invention relates to compounds that can be used as prodrugs, in particular nucleoside and triphosphate prodrugs, and a method for producing these compounds. The object of the present invention...
DE102014210662A1 Device and method for obtaining glycoglycerolipids and glycosphingolipids from lipoid phases  
The present invention relates to a device and method for the gentle and hydrolysis-free separation of glycoglycerolipids as well as glycoglycerolipids and glycosphingolipids from a lipoid phase...
DE102014208194A1 Purification of epidaunorubicin  
The present invention relates to a process for the purification of epidaunorubicin, in particular the removal of the impurity epi-feudomycin as occurs as a by-product in the biotechnological...
DE102014001464A1 RNAi technology  
Ribonucleic acids (RNAs) can be blocked by small inhibitory RNAs. In this way, genes off. This mechanism known as RNA interference was first described by Andrew Fire and Craig Mello. For the...
DE602004009038T3 Improved method for bisulfite treatment by  
The present application is directed to a method for performing a bisulfite reaction to determine methylation positions in a nucleic acid, i.e. methylated and non-methylated cytosines, whereby the...
DE112013004650T5 Multiplexpyrosequenzierung using nichtinterferierender, noise-terminating Polynukleotididentifikationstags  
The present disclosure relates generally to a multiplexing method for analyzing samples, comprising the Polynukleotidamplifikation to production of amplified products, wherein one or more target...
DE102013111487A1 The bispecific antibody fragment and pharmaceutical combination preparation with such a  
The invention relates to a bispecific antibody fragment (10) with a first detection point (12) and at least a second detection point (14), which specifically recognize each at least one structure...
DE19547958B4 Anthracycline derivatives  
Anthracycline analog of formula A wherein R1 is a hydrogen atom or a hydroxy or methoxy group; R2 and R3 are each hydroxyl groups or one of R2 and R3 is a hydroxy group and the other is a hydrogen...
DE102013006487A9 Iterative assembly and disassembly of predetermined, artificial DNA constructs and the specific exchange of functional genetic elements  
A variety of assembly methods for higher-order DNA constructs for the integration of molecular function have been described and also patented. There are no uniform concepts for the targeted...
DE602004006133T3 NEW GALACTOOLIGOSACCHARIDZUSAMMENSETZUNG AND PREPARATION THEREOF  
Novel strains of Bifidobacterium hifidum capable of producing a novel galactosidase enzyme activity that converts lactose to a novel mixture of galactooligosaccharides. The mixture of...
DE102013105144A1 The pharmaceutical combination product with an anti-idiotype antibody fragment  
The invention relates to a pharmaceutical combination preparation (10), in particular to suppression of an immune response, preferably a humoral immune response against a therapeutic organism...
DE112004000265B4 Novel photolabile protecting groups for improved processes for the production of oligonucleotide arrays  
Use of a compound having the general formula (1): in which R1 Is COOY, where Y is selected from the group consisting of an optionally substituted alkyl group having up to 10 carbon atoms on the...
DE102013006487A1 Iterative assembly and disassembly of predetermined, artificial DNA constructs and the specific exchange of functional genetic elements  
A variety of assembly methods for higher-order DNA constructs for the integration of molecular function have been described and also patented. There are no uniform concepts for the targeted...
DE60022612T3 VALLEY GEN NUCLEOTIDE  
This application discloses methods for the preparation of L-amino acids, which comprises fermentation of a desired L-amino acid-producing bacteria in which at least the tal gene is amplified. In...
DE112012003416T5 A process for the preparation of 2- (4-Methoxycarbonylpyrazol-1-yl) adenosine and 2- (4-ethoxycarbonyl-1-yl) adenosine  
A process for the preparation of 2- (4-Methoxycarbonylpyrazol-1-yl) adenosine of the formula Ia and 2- (4-ethoxycarbonyl-1-yl) adenosine of the formula Ib by reaction of 2-Hydrazinoadenosin of...
DE69828076T3 SYNTHESIS OF sulfurated Oligonucleotides  
Methods for the formation of sulfurized oligonucleotides are provided. The methods allow for the formation of phosphorothioate linkages in the oligonucleotides or derivatives, without the need for...
DE102012221519A1 Process for the isolation of rhamnolipids  
The invention relates to a method for isolating rhamnolipids
DE69333623T3 Cloning and Expression of GONADOTROPINRELEASING HORMONE  
The present invention relates to the GnRH-R genes and proteins. The DNA sequences disclosed herein may be engineered into expression systems designed for the production of GnRH-R and/or cell lines...